Natural product Erianin: mitigating FOLFOX toxicity and enhancing against colorectal cancer
IntroductionColorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects....
Saved in:
| Main Authors: | Fuqin Yang, Zeqiao Li, Haishan Zhang, Mingxiao Zhang, Zhenwei He, Xiaoqin Zheng, Yingru Zhu, Pei Long, Ruirui Ding, Zhengbin Lin, Lijuan Deng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2025.1650197/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
by: Yanhong Deng, et al.
Published: (2015-08-01) -
Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt/β-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo
by: Lingxue Tang, et al.
Published: (2024-11-01) -
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism
by: Lili Yan, et al.
Published: (2025-02-01) -
High-salt diet decreases FOLFOX efficacy via gut bacterial tryptophan metabolism in colorectal cancer
by: Yufei Deng, et al.
Published: (2025-02-01) -
Modulation of the KEAP1-NRF2 pathway by Erianin: A novel approach to reduce psoriasiform inflammation and inflammatory signaling
by: Yan Hongmei, et al.
Published: (2025-07-01)